Emerging drug targets for colon cancer: A preclinical assessment

References

• American Cancer Society. Colorectal cancer facts & figures 2020–2022. Atlanta: American Cancer Society; 2020.
   Google Scholar
• SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. [Cited 2021 Sept 27].
   Google Scholar
• Zacharakis M, Xynos ID, Lazaris A, et al. Predictors of survival in stage IV metastatic colorectal cancer. Anticancer Res. 2010;30:653–660.
   PubMed Web of Science ®Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714–727.
   PubMed Web of Science ®Google Scholar
• Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:22.
   PubMed Web of Science ®Google Scholar
• Yu Z, Pestell TG, Lisanti MP, et al. Cancer stem cells. Int J Biochem Cell Biol. 2012;44:2144–2151.
   PubMed Web of Science ®Google Scholar
• Wang H, Gong P, Chen T, et al. Colorectal cancer stem cell states uncovered by simultaneous single-cell analysis of transcriptome and telomeres. Adv Sci (Weinh). 2021;8(8):2004320.
   PubMedGoogle Scholar
• Milanovic M, Fan DNY, Belenki D, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96–100.
   PubMed Web of Science ®Google Scholar
• Francescangeli F, Contavalli P, De Angelis ML, et al. A pre-existing population of ZEB2+ quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. J Exp Clin Cancer Res. 2020;39:2.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xia L, Wang H, et al. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018;9:33403–33415.
   PubMedGoogle Scholar
• Liao W-T, Ye Y-P, Deng Y-J, et al. Metastatic cancer stem cells: from the concept to therapeutics. Am J Stem Cells. 2014;3:46–62.
   PubMedGoogle Scholar
• Dandawate P, Padhye S, Ahmad A, et al. Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv Transl Res. 2013;3:165–182.
   PubMed Web of Science ®Google Scholar
• Dalerba P, Dylla SJ, Park I-K, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104:10158–10163.
   PubMed Web of Science ®Google Scholar
• Wang J-Y, Chang -C-C, Chiang -C-C, et al. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem. 2012;113:1733–1743.
   PubMed Web of Science ®Google Scholar
• Kopenhaver J, Crutcher M, Waldman SA, et al. The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission. Expert Opin Biol Ther. 2021;21:1335–1345.
   PubMed Web of Science ®Google Scholar
• Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.
   PubMed Web of Science ®Google Scholar
• MacDonagh L, Gray SG, Breen E, et al. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 2018;428:117–126.
   PubMed Web of Science ®Google Scholar
• Todaro M, Francipane MG, Medema JP, et al. Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2010;138:2151–2162.
   PubMed Web of Science ®Google Scholar
• Tate CM, Pallini R, Ricci-Vitiani L, et al. A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death Differ. 2012;19:1644–1654.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13:165.
   PubMed Web of Science ®Google Scholar
• Jung Y-S, Park J-I. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Exp Mol Med. 2020;52:183–191.
   PubMed Web of Science ®Google Scholar
• Song L, Li Y, He B, et al. Development of small molecules targeting the wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer. Clin Colorectal Cancer. 2015;14:133–145.
   PubMed Web of Science ®Google Scholar
• Klose J, Eissele J, Volz C, et al. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/β-catenin signaling in CD133+ human colorectal cancer cells. BMC Cancer. 2016;16:896.
   PubMed Web of Science ®Google Scholar
• Madan B, Ke Z, Harmston N, et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene. 2016;35:2197–2207.
   PubMed Web of Science ®Google Scholar
• Cho Y-H, Ro EJ, Yoon J-S, et al. Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells. Cell Commun Signal. 2020;18:38.
   PubMed Web of Science ®Google Scholar
• Jang M-K, Mashima T, Seimiya H. Tankyrase inhibitors target colorectal cancer stem cells via AXIN-dependent downregulation of c-KIT tyrosine kinase. Mol Cancer Ther. 2020;19:765–776.
   PubMed Web of Science ®Google Scholar
• de Almeida GC, Oliveira LFS, Predes D, et al. Piperine suppresses the Wnt/β-catenin pathway and has anti-cancer effects on colorectal cancer cells. Sci Rep. 2020;10:11681.
   PubMed Web of Science ®Google Scholar
• Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25:6817–6830.
   PubMed Web of Science ®Google Scholar
• Zeligs KP, Neuman MK, Annunziata CM. Molecular pathways: the balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-κB signaling for cancer treatment. Clin Cancer Res. 2016;22:4302–4308.
   PubMed Web of Science ®Google Scholar
• Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. 2014;2:823–830.
   PubMed Web of Science ®Google Scholar
• de Almagro MC, Vucic D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol. 2012;34:200–211.
   PubMedGoogle Scholar
• Chen DJ, Huerta S. Smac mimetics as new cancer therapeutics. Anticancer Drugs. 2009;20:646–658.
   PubMed Web of Science ®Google Scholar
• Tafani M, Pucci B, Russo A, et al. Modulators of HIF1α and NFkB in cancer treatment: is it a rational approach for controlling malignant progression? Front Pharmacol. 2013;4:13.
   PubMed Web of Science ®Google Scholar
• Prescott JA, Cook SJ. Targeting ikkβ in cancer: challenges and opportunities for the therapeutic utilisation of ikkβ inhibitors. Cells. 2018;7:115.
   Web of Science ®Google Scholar
• Xu X, Wang J, Han K, et al. Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cells. Cancer Sci. 2018;109:1220–1229.
   PubMed Web of Science ®Google Scholar
• Mehta A, Patel BM. Therapeutic opportunities in colon cancer: focus on phosphodiesterase inhibitors. Life Sci. 2019;230:150–161.
   PubMed Web of Science ®Google Scholar
• Ataimish AH, Al-Shawi N, Al-Qurtas MM. Evaluation of chemopreventive response of pentoxiphylline and sildenafil in colorectal carcinoma experimentally induced in rats: comparative study with 5-fluorouracil. 2015.
   Google Scholar
• Kim DU, Kwak B, Kim S-W. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer. Biochem Biophys Res Commun. 2019;508:825–831.
   PubMed Web of Science ®Google Scholar
• McEwan DG, Brunton VG, Baillie GS, et al. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase. Cancer Res. 2007;67:5248–5257.
   PubMed Web of Science ®Google Scholar
• Murata K, Kameyama M, Fukui F, et al. Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility. Clin Exp Metastasis. 1999;17:525–530.
   PubMed Web of Science ®Google Scholar
• Piazza GA, Chen X, Ward A, et al. Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity. Oncology Signaling. 2020;3:1–6.
   Google Scholar
• Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19:533–552.
   PubMed Web of Science ®Google Scholar
• Pantsar T. The current understanding of KRAS protein structure and dynamics. Comput Struct Biotechnol J. 2020;18:189–198.
   PubMed Web of Science ®Google Scholar
• Tran TH, Chan AH, Young LC, et al. KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation. Nat Commun. 2021;12:1176.
   PubMed Web of Science ®Google Scholar
• Zenonos K, Kyprianou K. RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol. 2013;5:97–101.
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–551.
   PubMed Web of Science ®Google Scholar
• Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci USA. 2012;109:5299–5304.
   PubMed Web of Science ®Google Scholar
• Hillig RC, Sautier B, Schroeder J, et al. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction. Proc Natl Acad Sci USA. 2019;116:2551–2560.
   PubMed Web of Science ®Google Scholar
• Pitari GM, Li P, Lin JE, et al. The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther. 2007;82:441–447.
   PubMed Web of Science ®Google Scholar
• Blomain ES, Pattison AM, Waldman SA. GUCY2C ligand replacement to prevent colorectal cancer. Cancer Biol Ther. 2016;17:713–718.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381:1535–1546.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–1813.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125:4139–4147.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19:462–468.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337.
   PubMed Web of Science ®Google Scholar
• Sahin IH, Akce M, Alese O, et al. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809–818.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–779.
   PubMed Web of Science ®Google Scholar
• Lenz H-J, Van Cutsem E, Luisa Limon M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2021;JCO2101015.
   Google Scholar
• Westcott PMK, Sacks NJ, Schenkel JM, et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat Cancer. 2021;2:1071–1085.
   PubMedGoogle Scholar
• Tran E, Robbins PF, Lu Y-C, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375:2255–2262.
   PubMed Web of Science ®Google Scholar
• Cabrera T, Collado A, Fernandez MA, et al. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens. 1998;52:114–123.
   PubMedGoogle Scholar
• Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19:620–626.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–398.
   PubMed Web of Science ®Google Scholar
• Guedan S, Calderon H, Posey AD, et al. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145–156.
   PubMed Web of Science ®Google Scholar
• Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–4023.
   PubMed Web of Science ®Google Scholar
• Qin D, Li D, Zhang B, et al. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology. 2020;9(1):1806009.
   PubMed Web of Science ®Google Scholar
• Castellarin M, Sands C, Da T, et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI Insight. 2020;5(14). doi:https://doi.org/10.1172/jci.insight.136012.
   Google Scholar
• Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell. 1989;57(2):327–334.
   PubMed Web of Science ®Google Scholar
• Danaee H, Kalebic T, Wyant T, et al. Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers. PLoS ONE. 2017;12(12):e0189953.
   PubMed Web of Science ®Google Scholar
• Magee MS, Kraft CL, Abraham TS, et al. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology. 2016;5(10):e1227897.
   PubMed Web of Science ®Google Scholar
• Magee MS, Abraham TS, Baybutt TR, et al. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res. 2018;6(5):509–516.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–459.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang Z, Yang Z, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA + metastatic colorectal cancers. Mol Ther. 2017;25(5):1248–1258.
   PubMed Web of Science ®Google Scholar
• Katz SC, Burga RA, McCormack E, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor–modified T-cell therapy for CEA + liver metastases. Clin Cancer Res. 2015;21(14):3149–3159.
   PubMed Web of Science ®Google Scholar
• Katz SC, Hardaway J, Prince E, et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Ther. 2020;27(5):341–355.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti–PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748–2763.
   PubMed Web of Science ®Google Scholar
• Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-Directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357–362.
   PubMed Web of Science ®Google Scholar